BMY BMY ブリストル・マイヤ―ズ スクイブBMYのチャート
BMYの企業情報
| symbol | BMY |
|---|---|
| 会社名 | Bristol-Myers Squibb Co. （BMY ブリストル・マイヤ―ズ スクイブ） |
| 分野（sector） | |
| 産業（industry） | |
| 業種 | 医薬品 医療関連（Health Care） |
| 概要 | 事業概要 ブリストル・マイヤーズ・スクイブ（Bristol-Myers Squibb Company）はバイオ医薬品の発見・開発・ライセンス供与・生産・マーケティング・流通・販売に従事するバイオ医薬品会社である。同社の医薬品製品は化学合成薬物、または小分子、生物製剤と呼ばれる生物学的プロセスから製造された製品を含む。小分子薬物は丸剤または錠剤の形態で経口投与される。生物製剤は注射または注入によって患者に投与される。同社の製品にはエムプリシティ、オピボ、スピリセル、ヤルボイ、エリクイス、オレンシア、バラクルード、C型肝炎フランチャイズ、レイヤタズフランチャイズ、サスティバフランチャイズを含む。同社はヒト免疫不全ウイルス（HIV）感染を含むウイルス学、腫瘍学; 免疫科学、心臓血管等の治療クラスの製品を提供する。同社の製品は世界中の卸売業者、小売薬局、病院、政府機関、医療従事者に販売される。 ブリストル・マイヤ―ズ・スクイブは米国大手の生物医薬品メ―カ―。主要製品は抗血小板剤｢プラビックス｣、高血圧・糖尿病性腎症治療薬｢アバプロ｣、HIV治療薬｢レイアタッツ｣、B型肝炎治療薬｢バラクル―ド｣、骨髄性白血病治療薬｢スプリセル｣、抗精神薬｢エビリファイ｣、大腸がん治療薬｢ア―ビタックス｣など。米国、欧州、メキシコ、日本、中国で製造。 Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. |
| 本社所在地 | 430 E. 29th Street 14th Floor New York NY 10016 USA |
| 代表者氏名 | Giovanni Caforio |
| 代表者役職名 | Chairman of the Board Chief Executive Officer |
| 電話番号 | +1 212-546-4000 |
| 設立年月日 | 1887年 |
| 市場名 | NYSE（ニューヨーク証券取引所） |
| ipoyear | 年 |
| 従業員数 | 23300人 |
| url | www.bms.com |
| nasdaq_url | |
| adr_tso | |
| EBITDA | EBITDA（百万ドル） 8583.00000 |
| 終値（lastsale） | |
| 時価総額（marketcap） | |
| 時価総額 | 時価総額（百万ドル） 77894.97000 |
| 売上高 | 売上高（百万ドル） 22561.00000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 76359.97000 |
| 当期純利益 | 当期純利益（百万ドル） 4976.00000 |
| 決算概要 | 決算概要 BRIEF: For the fiscal year ended 31 December 2018 Bristol-Myers Squibb Co revenues increased 9% to $22.56B. Net income before extraordinary items increased 27% to $4.98B. Revenues reflect United States segment increase of 11% to $12.59B Europe segment increase of 13% to $5.66B. Net income benefited from Site exit costs and other decrease of 79% to $79M (expense) Other Non Rec. |
BMYのテクニカル分析
BMYのニュース
Bristol Myers Squibb to Participate in the Guggenheim Healthcare Talks 2023 Oncology Conference 2023/02/03 11:59:00 Business Wire
NEW YORK--(BUSINESS WIRE)---- $BMY #BMS--Bristol Myers Squibb to Participate in the Guggenheim Healthcare Talks 2023 Oncology Conference
Bristol-Myers Squibb Company (NYSE: BMY): Can The Stock Still Lose Despite An 0.65% YTD Gain? 2023/02/02 21:00:00 Marketing Sentinel
Bristol-Myers Squibb Company (NYSE:BMY)’s traded shares stood at 3.79 million during the latest session, with the company’s beta value hitting 0.42. At the last check today, the stock’s price was $72.42, to imply an increase of 1.66% or $1.19 in intraday trading. The BMY share’s 52-week high remains $81.43, putting it -12.44% down since that … Bristol-Myers Squibb Company (NYSE: BMY): Can The Stock Still Lose Despite An 0.65% YTD Gain? Read More »
Bristol-Myers Squibb (BMY) Q4 2022 Earnings Call Transcript 2023/02/02 19:00:21 The Motley Fool
BMY earnings call for the period ending December 31, 2022.
Bristol-Myers Squibb Company (BMY) Q4 2022 Earnings Call Transcript 2023/02/02 17:06:04 Seeking Alpha
Bristol-Myers Squibb Company (NYSE:NYSE:BMY) Q4 2022 Earnings Conference Call February 2, 2023 9:00 AM ETCompany ParticipantsTimothy Power - VP & Head, IRGiovanni Caforio - Chairman…
The Big Pharma axe: Merck cuts chikungunya vax, Bristol Myers drops CytomX-partnered programs, and more 2023/02/02 16:51:42 Endpoints News
As fourth quarter earnings come in, Big Pharmas are disclosing changes to their pipelines during their investor calls, and sometimes more quietly in presentation appendices. Merck dropped its chikungunya vaccine candidate, which completed a Phase II study. Merck acquired the vaccine through its purchase of Themis Bioscience in 2020. In
Bristol-Myers Squibb: Cash Rich And Trades Under 10x PE (NYSE:BMY) 2023/01/08 13:10:00 Seeking Alpha
Bristol-Myers Squibb is a high quality business that''s currently on sale. See why I find BMY stock to be a Buy for potentially strong long-term returns.
Biking the Globe for C2C4C 2023/01/05 20:35:00 Accesswire
NORTHAMPTON, MA / ACCESSWIRE / January 5, 2023 / Bristol Myers Squibb Company: Originally published on Bristol Myers Squibb News & Perspectives "A bicycle ride around the world begins with a single pedal stroke." A handful of inspirational words from author Scott Stoll served as the rallying cry for more than 350 Bristol Myers Squibb employees representing 23 nations who successfully trained and participated in four regional bicycle rides collectively known as C2C4C. The 2022 C2C4C journey covered nearly 7,000 miles traversing mountain ranges and scenic plains in challenging rain, wind and heat. Along the way, our employees cycled through cities and towns such as Boudry, Switzerland, Princeton, New Jersey, Otemachi, Tokyo, Japan, and Pucon, Chile. Blanca Bedoya, sales representative, Hematology, who is based in Colombia, is a cancer survivor who participated in the inaugural C2C4C ride in Latin America this year. "C2C4C for me is an opportunity to link my work with my mission in life to grow, improve myself and understand that when I strive to be better and achieve something, there is always a purpose," said Bedoya. "I also ride for my family, my husband and children.
Looking At Bristol-Myers Squibb''s Recent Unusual Options Activity 2023/01/05 13:27:30 Benzinga
Someone with a lot of money to spend has taken a bullish stance on Bristol-Myers Squibb (NYSE: BMY ). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga. Whether this is an institution or just a wealthy individual, we don''t know. But when something this big happens with BMY, it often means somebody knows something is about to happen. So how do we know what this whale just did? Today, Benzinga ''s options scanner spotted 14 uncommon options trades for Bristol-Myers Squibb. This isn''t normal. The overall sentiment of these big-money traders is split between 50% bullish and 50%, bearish. Out of all of the special options we uncovered, 7 are … Full story available on Benzinga.com
Minovia Therapeutics appoints Maha Radhakrishnan, Chief Medical Officer at Biogen, as board member 2023/01/05 13:00:00 Benzinga
TIRAT HACARMEL, Israel, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Minovia Therapeutics (Minovia) , a clinical-stage company focused on developing novel Mitochondrial Augmentation Technology (MAT) to fight mitochondrial diseases, has announced a Board appointment. Maha Radhakrishnan, M.D., joins the board at a time in which the company advances clinical programs in primary mitochondrial diseases and hematological disorders associated with mitochondrial dysfunction. As a trained physician, Maha is a senior leader with extensive pharmaceutical and biotech experience covering clinical development, post-marketing regulatory activities, medical affairs, safety, and reimbursement requirements. Maha is the Chief Medical Officer of Biogen, and in her previous roles, she served as Senior Vice President and Global Head of Medical, Primary Care Business Unit at Sanofi, Senior Vice President and Head of Worldwide Medical at Bioverativ Therapeutics Inc., and Head of Europe & Canada Medical and US Medical at Biogen.
Congressman Sells Stocks At End Of 2022 And Retires From Office: Taking Profits Or Warning Sign? 2023/01/03 21:44:25 Benzinga
A member of Congress sold out of his positions in several stocks at the end of 2022. The move came as he finished his term serving the state of Texas and announced his retirement. What Happened: Last year turned out to be a disappointing one for many investors, with the S&P 500, as tracked by the SPDR S&P 500 Global ETF (NYSE: SPY ), having its worse year since 2008. Congressman Van Taylor (R-TX) disclosed several stock transactions in late December, from trades made on Nov. 28, 2022. The transactions were: Sold $100,000 to $250,000 Bristol Myers Squibb (NYSE: BMY ) Sold $500,000 to $1,000,000 Chevron Corporation (NYSE: CVX ) Sold $1,000,000 to $5,000,000 Eli Lilly (NYSE: LLY ) Sold $1,000,000 to $5,000,000 Exxon Mobil (NYSE: XOM ) Sold $250,000 to … Full story available on Benzinga.com
Bristol Myers says Merck-partnered blood cancer therapy met main goal in Phase 3 trial 2022/10/31 11:42:01 Seeking Alpha
Bristol Myers Squibb (BMY) announced Monday that Reblozyl, an FDA-approved anemia therapy the company develops in partnership with Merck (MRK), reached the primary and key…
Bristol Myers Squibb Announces Positive Topline Results of Phase 3 COMMANDS Trial 2022/10/31 10:59:00 Business Wire
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--Bristol Myers Squibb Announces Positive Topline Results of Phase 3 COMMANDS Trial
Bristol-Myers Squibb And Gilead – Still A Buy After Strong Q3? (NYSE:BMY) 2022/10/28 12:30:00 Seeking Alpha
Both Bristol-Myers Squibb (BMY) and Gilead (GILD) reported solid Q3 results. Check out whether I am still a buyer despite the outperformance of both stocks.
Strong Fundamentals Make Bristol-Myers Squibb Stock A Real Value 2022/10/27 21:08:27 ValueWalk
Bristol-Myers Squibb (NYSE:BMY) posted a modest gain after a double beat on earnings. The company continues to display strong fundamentals and a robust pipeline. Although growth investors may not be pleased, Bristol-Myers Squibb stock remains a strong value stock. Bristol-Myers Squibb Co (NYSE:BMY) posted a small gain after an earnings report; the company beat its […]